CERS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 186.77 -- higher than 83.86% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 9.72, Cerus Corp has a higher such ratio than 85.26% of stocks in our set.
As for revenue growth, note that CERS's revenue has grown 22.42% over the past 12 months; that beats the revenue growth of 80.81% of US companies in our set.
Stocks that are quantitatively similar to CERS, based on their financial statements, market capitalization, and price volatility, are EPZM, JG, MRAM, PSNL, and KIN.
CERS's SEC filings can be seen here. And to visit Cerus Corp's official web site, go to www.cerus.com.
Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October 3rd through October 5th. This year’s Virtual Annual Meeting remains one of the largest scientific symposiums focused on the field of transfusion medicine. Scientists and clinicians from around the globe will share the latest research and practice-changing resources in the fields of blood and biotherapies.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the following two conferences: The Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 15th at 2:00 P.M. ET. The H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16th at 12:00 P.M. ET. A live webcast o
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch. “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components,” said William ‘Obi’ Greenman, Cerus
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driven by robust year-over-year platelet kit sales growth in the U.S. and strong plasma and illuminator sales in our EMEA region. Total revenue comprised of (in millions, except %): Q2 2020 Q2 2019 Change $ Change% Product Revenue $ 21.5 $ 18.2 $ 3.3 18.1% Government